1. **The Progression of the IBD-U™ Initiative**

**A traveling center of excellence**

**2019 co-Chairs**
- Russell D. Cohen, MD, FACG, AGAF
  Director, Inflammatory Bowel Disease Center
  University of Chicago Medicine
- David T. Rubin, MD, FACP, AGAF, FACG
  FASGE
  Section Chief, Gastroenterology, Hepatology and Nutrition
  University of Chicago Medicine
  Chicago, IL

**2019 APP Faculty**
- Mary Ayers, EdD-AN
- Ashley A. Bachmeyer, APN, FNP-BC
- Janice E. Cadwell ARNP, CNN, FAAN
- Michael Rubin, MD, MS, ONS, CGRN
- Sushila Dale, MD

**Unique Features**
- Provider tools, gamified learning, multidisciplinary panels

**3. Cumulative Attendee Demographics**

<table>
<thead>
<tr>
<th>Degree</th>
<th>%</th>
<th>Specialty</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD/DO</td>
<td>48%</td>
<td>Gastroenterology</td>
<td>25%</td>
</tr>
<tr>
<td>DO</td>
<td>1%</td>
<td>IBD</td>
<td>13%</td>
</tr>
<tr>
<td>PA</td>
<td>15%</td>
<td>Internal Medicine</td>
<td>15%</td>
</tr>
<tr>
<td>PharmD/RPh</td>
<td>22%</td>
<td>Family/General Practice</td>
<td>13%</td>
</tr>
<tr>
<td>Other HCP</td>
<td>1%</td>
<td>Nursing</td>
<td>1%</td>
</tr>
<tr>
<td>NP</td>
<td>71%</td>
<td>Other</td>
<td>2%</td>
</tr>
</tbody>
</table>

**Patients Seen**
- Attendees see an average of 8 patients per month with IBD

**Practice Patterns**
- Of those who treat regardless of severity, 82% use biologics in at least 50% of patients
- I do not prescribe biologic therapy for my patients

**4. Educational Impact**

**Impact on Patient Health**
- 100% of attendees report that the activity was better than most for positively impacting patient health

**Educational Impact**
- Planned Practice Changes: 96%
  - Have implemented practice changes such as implementing the latest clinical advances; 80% of these have observed improvements in patient health
- Impact of activities: 97%
  - Average Patient Impact: >6,000

**Average Increase in Learning**
- 78%
  - Relative increase in knowledge and competence

**5. Application to Future Programs**

**Persisting Needs**
- Knowledge and confidence was more discordant on the topic of diagnosis
- Attendees lack consensus on when to switch to a new biologic vs intensifying TNFi treatment
- Knowledge is lacking regarding assessment of risk in patients being treated for IBD

**Planned 2019-2020 Initiative**
- Relevant Cases
  - “Best Of” Web Posting
  - Addressing FAQs
  - Refined recruitment
  - Multidisciplinary panels